AR057323A1 - Metodo para la prediccion de la respuesta a un tratamiento - Google Patents

Metodo para la prediccion de la respuesta a un tratamiento

Info

Publication number
AR057323A1
AR057323A1 ARP060102149A ARP060102149A AR057323A1 AR 057323 A1 AR057323 A1 AR 057323A1 AR P060102149 A ARP060102149 A AR P060102149A AR P060102149 A ARP060102149 A AR P060102149A AR 057323 A1 AR057323 A1 AR 057323A1
Authority
AR
Argentina
Prior art keywords
growth factor
response
treatment
marker gene
patient
Prior art date
Application number
ARP060102149A
Other languages
English (en)
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35511140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057323(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR057323A1 publication Critical patent/AR057323A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G01N33/57557—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/57515—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
ARP060102149A 2005-08-12 2006-05-24 Metodo para la prediccion de la respuesta a un tratamiento AR057323A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05017663 2005-08-12

Publications (1)

Publication Number Publication Date
AR057323A1 true AR057323A1 (es) 2007-11-28

Family

ID=35511140

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102149A AR057323A1 (es) 2005-08-12 2006-05-24 Metodo para la prediccion de la respuesta a un tratamiento

Country Status (32)

Country Link
US (2) US7700299B2 (enExample)
EP (2) EP2196547B1 (enExample)
JP (1) JP2009504142A (enExample)
KR (2) KR20080034922A (enExample)
CN (2) CN101705287A (enExample)
AR (1) AR057323A1 (enExample)
AT (2) ATE493514T1 (enExample)
AU (2) AU2006281746B2 (enExample)
BR (1) BRPI0615001A2 (enExample)
CA (1) CA2616913A1 (enExample)
CL (1) CL2010000720A1 (enExample)
CR (1) CR9686A (enExample)
CY (1) CY1111612T1 (enExample)
DE (1) DE602006019265D1 (enExample)
DK (1) DK1915460T3 (enExample)
EC (1) ECSP088171A (enExample)
ES (1) ES2356066T3 (enExample)
HR (1) HRP20110171T1 (enExample)
IL (1) IL188923A0 (enExample)
MA (1) MA31549B1 (enExample)
MX (1) MX2008001926A (enExample)
NO (1) NO20080371L (enExample)
NZ (1) NZ565270A (enExample)
PL (1) PL1915460T3 (enExample)
PT (1) PT1915460E (enExample)
RS (1) RS51859B (enExample)
RU (2) RU2408735C2 (enExample)
SI (1) SI1915460T1 (enExample)
TW (1) TW200741010A (enExample)
UA (1) UA93989C2 (enExample)
WO (1) WO2007019899A2 (enExample)
ZA (1) ZA201102688B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CN109395082A (zh) * 2000-05-19 2019-03-01 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
KR20070038557A (ko) 2004-07-22 2007-04-10 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0518086A (pt) * 2004-12-07 2008-10-28 Genentech Inc métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação
BRPI0518104B8 (pt) * 2005-01-21 2021-05-25 Genentech Inc artigo industrializado e uso de anticorpo her2
CN101163503B (zh) * 2005-02-23 2013-05-08 健泰科生物技术公司 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
JP2009505658A (ja) * 2005-08-24 2009-02-12 ブリストル−マイヤーズ スクイブ カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
TWI352199B (en) 2007-03-02 2011-11-11 Genentech Inc Predicting response to a her inhibitor
JP5433189B2 (ja) * 2007-09-28 2014-03-05 承一 尾崎 Ｍｐｏ−ａｎｃａ関連血管炎の被験者に対する治療の効果を予測する材料を提供する方法
WO2009086197A1 (en) * 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
CA2710680C (en) * 2007-12-26 2018-10-16 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0906049A8 (pt) * 2008-03-14 2018-06-26 Genentech Inc método para determinar se um câncer em um paciente é resistente ao tratamento com um agente antimitótico, método para tratar um paciente com câncer que é resistente ao agente antimitótico e método de tratamento
EP2288727B1 (en) * 2008-05-14 2013-07-10 Genomic Health, Inc. Predictors of patient response to treatment with egf receptor inhibitors
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
ES2637411T3 (es) 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
CA2749817A1 (en) * 2009-01-15 2010-07-22 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of her-2 expression
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
RU2012148398A (ru) * 2010-04-18 2014-05-27 Иеда Рисеч Энд Девелопмент Ко. Лтд. МОЛЕКУЛЫ И СПОСОБЫ ПРИМЕНЕНИЯ МОЛЕКУЛ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНЕЙ, АССОЦИИРОВАННЫХ С ErbB/ErbB ЛИГАНДАМИ
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
SG191855A1 (en) * 2011-01-07 2013-08-30 Elcelyx Therapeutics Inc Chemosensory receptor ligand-based therapies
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
CN103959065B (zh) * 2011-10-06 2018-07-17 Aveo制药公司 预测肿瘤对抗erbb3抗体的应答
LT4403228T (lt) 2011-10-14 2025-10-27 Her2 dimerizacijos inhibitoriaus pertuzumabo panaudojimo būdai ir gamybos produktas, į kurio sudėtį jis įeina
NZ626578A (en) 2012-01-06 2016-11-25 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
ES2832773T3 (es) 2012-01-06 2021-06-11 Anji Pharma Us Llc Composiciones de biguanida y métodos de tratamiento de trastornos metabólicos
MA38567A1 (fr) 2013-04-16 2017-09-29 Genentech Inc Variantes de pertuzumab et leur évaluation
WO2015017529A2 (en) * 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
EP2876442A1 (en) * 2013-11-22 2015-05-27 Institut de Cancérologie de l'Ouest Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer
RU2725093C2 (ru) 2014-04-25 2020-06-29 Дженентек, Инк. Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
WO2016011432A2 (en) 2014-07-17 2016-01-21 Czerniecki Brian J Identification of immunogenic mhc class ii peptides for immune-based therapy
JP6822980B2 (ja) 2015-05-30 2021-01-27 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性転移性乳癌の治療方法
CA2992925A1 (en) * 2015-07-17 2017-01-26 The Trustees Of The University Of Pennsylvania Identification of immunogenic mhc class ii peptides for immune-based therapy
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN105403704A (zh) * 2015-12-31 2016-03-16 苏州市博纳泰科生物技术有限公司 Her-2的荧光免疫层析检测方法及试剂盒
TW201818940A (zh) 2016-11-04 2018-06-01 美商建南德克公司 Her2陽性乳癌之治療
EP3562844A1 (en) 2016-12-28 2019-11-06 Genentech, Inc. Treatment of advanced her2 expressing cancer
CA3047349C (en) 2017-01-17 2020-09-22 Genentech, Inc. Subcutaneous her2 antibody formulations
LT3589661T (lt) 2017-03-02 2024-02-12 Genentech, Inc. Adjuvantinis her2 atžvilgiu teigiamo krūties vėžio gydymas
CN110536969A (zh) 2017-04-24 2019-12-03 豪夫迈·罗氏有限公司 跨膜或近膜域中的erbb2/her2突变
MY199134A (en) 2018-05-25 2023-10-17 Bioneer Corp Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis related diseases and respiratory diseases, comprising same
EP4171748A1 (en) 2020-06-29 2023-05-03 Genentech, Inc. Pertuzumab plus trastuzumab fixed dose combination
EP4568994A1 (en) * 2022-08-09 2025-06-18 Heligenics, Inc. Method for evaluating clinical relevance of genetic variance

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
CN101412758A (zh) 1996-10-18 2009-04-22 基因技术股份有限公司 抗ErbB2抗体
ES2329437T3 (es) 1999-06-25 2009-11-26 Genentech, Inc. Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2.
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7081340B2 (en) 2002-03-13 2006-07-25 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
DK2263691T3 (da) * 2002-07-15 2012-10-22 Hoffmann La Roche Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4)
AU2003302821B2 (en) * 2002-12-11 2009-05-07 Cell Signaling Technology, Inc. Method for predicting the response to HER2-directed therapy
CA2515096A1 (en) 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
BRPI0408928A (pt) 2003-04-01 2006-09-12 Monogram Biosciences Inc métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente
KR101126560B1 (ko) 2003-05-30 2012-04-05 도꾜 다이가꾸 약제 반응 예측 방법
US20060204966A1 (en) 2003-08-01 2006-09-14 Spector Neil L Treatment of cancers expressing p95 erbb2
EP1682675A2 (en) 2003-10-28 2006-07-26 Bayer HealthCare AG Methods and compositions for the response prediction of malignant neoplasia to treatment
TWM256978U (en) * 2004-04-02 2005-02-11 Nventec Appliances Corp Electronic device
BRPI0518086A (pt) * 2004-12-07 2008-10-28 Genentech Inc métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação
RU2300111C2 (ru) * 2005-06-15 2007-05-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ прогнозирования течения заболевания раком молочной железы

Also Published As

Publication number Publication date
RS51859B (sr) 2012-02-29
KR20110074921A (ko) 2011-07-04
EP2196547A1 (en) 2010-06-16
JP2009504142A (ja) 2009-02-05
WO2007019899A8 (en) 2010-08-05
US20100112603A1 (en) 2010-05-06
EP1915460A2 (en) 2008-04-30
US20070037228A1 (en) 2007-02-15
RU2008108907A (ru) 2009-09-20
RU2408735C2 (ru) 2011-01-10
HRP20110171T1 (hr) 2011-04-30
ES2356066T3 (es) 2011-04-04
DE602006019265D1 (de) 2011-02-10
PL1915460T3 (pl) 2011-05-31
BRPI0615001A2 (pt) 2011-04-26
KR20080034922A (ko) 2008-04-22
AU2006281746B2 (en) 2011-06-23
NZ565270A (en) 2011-05-27
AU2006281746A1 (en) 2007-02-22
CN101705287A (zh) 2010-05-12
ATE539171T1 (de) 2012-01-15
WO2007019899A3 (en) 2007-04-05
EP2196547B1 (en) 2011-12-28
CY1111612T1 (el) 2015-10-07
ZA201102688B (en) 2012-01-25
AU2011202339A1 (en) 2011-06-09
NO20080371L (no) 2008-05-09
MA31549B1 (fr) 2010-08-02
US7700299B2 (en) 2010-04-20
UA93989C2 (ru) 2011-03-25
MX2008001926A (es) 2008-03-24
TW200741010A (en) 2007-11-01
DK1915460T3 (da) 2011-01-31
CN101405405A (zh) 2009-04-08
WO2007019899A2 (en) 2007-02-22
CR9686A (es) 2008-02-20
ECSP088171A (es) 2008-03-26
SI1915460T1 (sl) 2011-04-29
ATE493514T1 (de) 2011-01-15
PT1915460E (pt) 2011-03-17
CA2616913A1 (en) 2007-02-22
RU2010115252A (ru) 2011-10-27
CL2010000720A1 (es) 2010-12-03
EP1915460B1 (en) 2010-12-29
IL188923A0 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
AR057323A1 (es) Metodo para la prediccion de la respuesta a un tratamiento
MX2007006529A (es) Seleccionar pacientes para terapia con un inhibidor her.
HN2008000346A (es) Secuencias de nucleotidos que codifican proteinas insecticidas
MX350533B (es) Biomarcadores de cancer pancreatico y usos de los mismos.
AR102518A1 (es) Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40
AR059433A1 (es) Identificacion y uso de genes blanco para el control de nematodos parasitos de plantas
ECSP17025787A (es) Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
AR046832A1 (es) Ensayos de rastreo y metodos de tratamiento de tumores
WO2004011624A3 (en) Double stranded rna structures and constructs, and methods for generating and using the same
PE20030659A1 (es) Metodo para la identificacion de enzimas marcadores tumorales
DOP2010000076A (es) Deteccion mejorada de expresion de mage-a
MX2019006565A (es) Medio de cultivo para celulas madre epiteliales y organoides que comprenden las celulas madre.
RU2013121000A (ru) Способ идентификации нативных пар фрагментов днк или рнк, присутствующих в одних и тех же живых клетках
PE20070356A1 (es) Metodo para el diseno de oligonucleotidos para tecnicas de biologia molecular
EP4428528A3 (en) Labeled nucleotide compositions and methods for nucleic acid sequencing
WO2018096375A3 (en) Determination of the receptive status of the endometrium
MX2025004103A (es) Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa
AR051523A1 (es) Metodo para medir la resistencia o sensibilidad a docetaxel
AR115018A1 (es) Método para aumentar el nivel de expresión de una molécula de ácido nucleico de interés en una célula
BRPI1008762B8 (pt) métodos para seleção de células de mamífero expressando uma proteína heteróloga, para produzir um produto de interesse e uso de um meio de cultura seletivo
CL2011000248A1 (es) Metodo para aumentar el crecimiento o diferenciacion in vitro en un cultivo de celulas o tejido, basado en la aplicacion de radio frecuencia pulsada (prf); y uso de dicho tratamiento.
MX2009009060A (es) Un metodo de identificacion de celulas que muestren sensibilidad a la modulacion de la señalizacion mediada por un receptor del factor de crecimiento de fibroplastos o una variante del mismo.
AR088363A1 (es) MATERIALES Y METODOS PARA LA DETECCION DEL EVENTO pDAB4472-1606 QUE CONTIENE EL GEN ARILOXIALCANOATO DIOXIGENASA (AAD-12) EN PLANTAS
RU2012149631A (ru) СПОСОБ ПОЛУЧЕНИЯ aRNA И СПОСОБ АНАЛИЗА ЭКСПРЕССИИ ГЕНА
CO2025014369A2 (es) Sistemas, composiciones y métodos para la detección del adn del cáncer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal